Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues
Firdaus, Zeba , Li, Xiaogang

International Journal of Molecular Sciences | October 30, 2024 | Volume: 25 | Issue: 21 | Pages: 11658

10.3390/ijms252111658 | PMID 39519209 Get It

Neurodegenerative disorders are major health concerns globally, especially in aging societies. The exploration of brain epigenomes, which consist of multiple forms of DNA methylation and covalent histone modifications, offers new and unanticipated perspective into the mechanisms of aging and neurodegenerative diseases. Initially, chromatin defects in the brain were thought to be static abnormalities from early development associated with rare genetic syndromes. However, it is now evident that mutations and the dysregulation of the epigenetic machinery extend across a broader spectrum, encompassing adult-onset neurodegenerative diseases. Hence, it is crucial to develop methodologies that can enhance epigenetic research. Several approaches have been created to investigate alterations in epigenetics on a spectrum of scales—ranging from low to high—with a particular focus on detecting DNA methylation and histone modifications. This article explores the burgeoning realm of neuroepigenetics, emphasizing its role in enhancing our mechanistic comprehension of neurodegenerative disorders and elucidating the predominant techniques employed for detecting modifications in the epigenome. Additionally, we ponder the potential influence of these advancements on shaping future therapeutic approaches.
ARSA Variant Associated With Late Infantile Metachromatic Leukodystrophy and Carrier Rate in Individuals of Ashkenazi Jewish Ancestry
Rabin, Rachel , Hirsch, Yoel , Booth, Kevin T. , Hall, Patricia , Yachelevich, Naomi, Mistry, Pramod K. , Ekstein, Josef , Pappas, John , Booth, Kevin T A , Hall, Patricia L

American Journal of Medical Genetics Part A | October 30, 2024 | Volume: 197 | Issue: 3 | Pages: No page available

10.1002/ajmg.a.63919 | PMID 39473378 Get It

ABSTRACTMetachromatic leukodystrophy (MLD) is a rare neurodegenerative lysosomal storage disease resulting from bi‐allelic pathogenic variants in the ARSA gene. MLD is distinguished clinically based on the age of onset into late‐infantile, juvenile, and adult. The late‐infantile type is the most severe phenotype presenting with hypotonia, weakness, gait abnormalities, which progresses to mental and physical decline leading to early death. MLD is considered to be pan‐ethnic and no founder variants have previously been described in the Ashkenazi Jewish population. We identified three unrelated individuals of Ashkenazi Jewish descent with homozygosity or compound heterozygosity for the c.178C>T (p.Arg60Trp) variant in the ARSA gene, with a phenotype consistent with late‐infantile MLD. The carrier frequency was calculated among 93,293 individuals of Ashkenazi Jewish descent through the Dor Yeshorim screening program and found to have a carrier frequency on 1 in 1554 or 0.06%, which may be representative of a founder variant. Molecular protein modeling showed that the variant affects regional folding. Late‐infantile MLD should be considered when the c.178C>T (p.Arg60Trp) variant in the ARSA gene is present in either the homozygous or the compound heterozygous states.
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
Reddy, Yogesh N.V. , Anstrom, Kevin J. , Blaustein, Robert O. , Bonaca, Marc P. , Corda, Stefano , Lam, Carolyn S.P., Lewis, Eldrin F. , Lindenfeld, JoAnn, McMullan, Ciaran J. , Mentz, Robert J. , O’Connor, Christopher, Patel, Mahesh J., Ponikowski, Piotr, Rosano, Giuseppe M.C., Saldarriaga, Clara , Senni, Michele, Udelson, James E. , Zannad, Faiez, Nishimura, Rick , Mentz, Robert J , Butler, Javed , Ezekowitz, Justin A. , Lam, Carolyn S.P., Ponikowski, Piotr , Senni, Michele , Voors, Adriaan A. , Zannad, Faı̈ez

European Journal of Heart Failure | October 30, 2024 | Volume: 27 | Issue: 2 | Pages: 209-218

10.1002/ejhf.3501 | PMID 39473305 Get It

Abstract Aims In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy. Methods The primary endpoint for VICTOR is time to first event for the composite of HHF or cardiovascular death. The trial will also assess the effect of vericiguat on time to cardiovascular death, time to HHF, total HHF, and all-cause death. As an event-driven trial, at least 1080 primary events are expected, but follow-up will continue until the targeted number of at least 590 cardiovascular deaths has been reached. Approximately 6000 participants will be randomized to vericiguat or placebo. Conclusion VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational guideline-directed medical therapy, in a compensated ambulatory HF population. VICTOR will add important information to the evidence of the effects of vericiguat across the spectrum of patients with HFrEF.
Outcomes and Complications of Mitral and Tricuspid Transcatheter Edge-to-edge Repair
Arnautovic, Jelena , Ya’qoub, Lina , Wajid, Zarghoona , Jacob, Chris , Murlidhar, Manish , Damlakhy, Ahmad , Walji, Mohammed , Wajid, Zarghoona

Interventional Cardiology: Reviews, Research, Resources | October 30, 2024 | Volume: 19 | Issue: No issue available | Pages: No page available

10.15420/icr.2024.08 | PMID 39569385 Get It

In the realm of innovative medical procedures, TEER (transcatheter edge-to-edge repair) has emerged as a promising field, showcasing significant growth and advancements. Mitral TEER has been performed for the last two decades; in contrast, tricuspid TEER is newer, with long-term outcomes pending. This article aims to provide a comprehensive review of the current literature, with a primary focus on outcomes and potential complications associated with both procedures. Both procedures carry a low risk of complications when done by experienced providers. A team approach involving specialists in cardiology, cardiothoracic surgery, cardiac imaging and heart failure ensures comprehensive care. A unified approach encompassing preprocedural workup, risk assessment, and standardised care throughout the procedure and recovery contributes to successful outcomes.
Robotics in orthopaedic surgery: The end of surgery or its future?
Oettl, Felix C. , Zsidai, Bálint , Oeding, Jacob F. , Hirschmann, Michael T. , Samuelsson, Kristian , Group, ESSKA Artificial Intelligence Working, Farshad, Mazda , Hirschmann, Michael T , Samuelsson, Kristian , Oettl, Felix C. , Oeding, Jacob F , Group, ESSKA Artificial Intelligence Working

Knee Surgery, Sports Traumatology, Arthroscopy | October 30, 2024 | Volume: 33 | Issue: 3 | Pages: 793-799

10.1002/ksa.12523 | PMID 39474855 Get It

Arthroscopic Iliopsoas Fractional Lengthening After Total Hip Arthroplasty: Utilization of the Iliopsoas Air Bursogram Technique for Safe and Efficient Access
Simon, Karissa N. , Meta, Fabien , Reuter, Zachary C. , Levy, Bruce A. , Krych, Aaron J. , Hevesi, Mario

Video Journal of Sports Medicine | October 30, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1177/26350254241283497 | PMID 40309245 Get It

Background: Patients with persistent symptomatic iliopsoas tendonitis following total hip arthroplasty may benefit from iliopsoas fractional lengthening. We present an arthroscopic approach utilizing an air bursogram that provides safe and predictable access to the iliopsoas tendon for efficient tendon lengthening without violating the capsule or unintentional instrumentation of the nearby medial neurovascular bundle. Indications: Arthroscopic iliopsoas fractional lengthening is indicated for patients with clinical evidence of symptomatic iliopsoas tendonitis following total hip arthroplasty and have no radiographic evidence of frank acetabular malpositioning. A diagnosis of iliopsoas tendinitis amenable to surgical management can be established with substantial but nondurable relief following image-guided anesthetic injection to the iliopsoas bursa. Technique Description: Under fluoroscopic guidance, an air bursogram is employed in the anatomic plane of the iliopsoas tendon to accurately identify its course. This allows for hip portal placement with precise subsequent instrumentation. This technique is preferred in the setting of postarthroplasty anatomy because it avoids capsular violation and the challenge of working in an altered anatomic space with a nearby, medially based neurovascular bundle. Results: Arthroscopic and endoscopic approaches to iliopsoas release have been shown to provide excellent functional and patient-reported outcomes in >85% of patients, and several studies have shown that an arthroscopic approach not only provides a less invasive technique but also results in comparable or improved clinical outcomes with lower revision rates compared to open release or acetabular cup revision. Our technique for arthroscopic iliopsoas fractional lengthening using the air bursogram is both safe and reproducible and offers distinct advantages, including maintenance of an intact capsule, visual confirmation of the correct anatomic structure to be released, and percutaneous access with standard arthroscopic access cannulas without the need for hip distraction. Conclusions: Arthroscopic fractional iliopsoas lengthening is a minimally invasive and successful treatment option for patients with persistent groin pain after total hip arthroplasty, especially without substantial acetabular component malpositioning. This technique includes using an air bursogram to safely identify and navigate to the iliopsoas tendon without violating the hip capsule, thereby reducing the risk of inadvertent instrumentation of adjacent critical neurovascular structures. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study
Suhr, Ole B. , Grogan, Martha , Silva, Ana , Karam, Chafic , Drachman, Brian , Zago, Wagner , Tripuraneni, Radhika , Kinney, Gene G. , Silva, Ana Martins da , Garcia-Pavia, Pablo , Drachman, Brian , Zago, Wagner , Tripuraneni, Radhika , Kinney, Gene G , Karam, Chafic

Amyloid | October 30, 2024 | Volume: 32 | Issue: 1 | Pages: 14-21

10.1080/13506129.2024.2420809 | PMID 39472768 Get It

Seizure Sources Can Be Imaged from Scalp EEG by Means of Biophysically Constrained Deep Neural Networks
Sun, Rui , Worrell, Gregory, He, Bin , He, Bin , Sohrabpour, Abbas , Joseph, Boney , Worrell, Gregory A.

Advanced Science | October 30, 2024 | Volume: 11 | Issue: 47 | Pages: No page available

10.1002/advs.202405246 | PMID 39473085 Get It

Abstract Seizure localization is important for managing drug‐resistant focal epilepsy. Here, the capability of a novel deep learning‐based source imaging framework (DeepSIF) for imaging seizure activities from electroencephalogram (EEG) recordings in drug‐resistant focal epilepsy patients is investigated. The neural mass model of ictal oscillations is adopted to generate synthetic training data with spatio‐temporal‐spectra features similar to ictal dynamics. The trained DeepSIF model is rigorously validated using computer simulations and in a cohort of 33 drug‐resistant focal epilepsy patients with high‐density (76‐channel) EEG seizure recordings, by comparing DeepSIF estimates with surgical resection outcome and seizure onset zone (SOZ). These findings show that the trained DeepSIF model outperforms other methods in estimating the spatial and temporal information of origins of ictal activities. It achieves a high spatial specificity of 96% and a low spatial dispersion of 3.80 ± 5.74 mm when compared to the resection region. The source imaging results also demonstrate good coverage of SOZ, with an average distance of 10.89 ± 10.14 mm (from the SOZ to the reconstruction). These promising results suggest that DeepSIF has significant potential for advancing noninvasive imaging of the origins of ictal activities in patients with focal epilepsy, aiding management of intractable epilepsy.
The In-Hospital Code Stroke: A Look Back and the Road Ahead
Kuczynski, Andrea M. , Freeman, William D. , Mooney, Lesia , Huang, Josephine F. , Demchuk, Andrew M., Khosravani, Houman , Freeman, William D , Mooney, Lesia H

The Neurohospitalist | October 29, 2024 | Volume: 15 | Issue: 2 | Pages: 124-132

10.1177/19418744241298035 | PMID 39544262 Get It

With increased patient volumes and complexity, stroke occurrence in hospitalized patients has become relatively more common. The process of activating a code stroke in-hospital differs in many institutions. An emergency team-based response to inpatient acute code stroke is warranted, with many protocols modeled similarly to the cardiac arrest response. However, several studies have demonstrated delays in recognition and management of acute stroke in-hospital as compared to those arriving directly to the emergency department (ED). Furthermore, there are several shared challenges with code stroke resuscitation in the ED and the ward, which include the assembly of ad hoc teams and requirement of access to urgent imaging. Delays in activating in-hospital code stroke contributes to increased morbidity, mortality, prolonged hospitalization, and associated health care costs. In the following commentary, we discuss the current landscape of acute in-hospital code stroke protocols, review the differences in neurologic outcomes between inpatient vs ED/out-of-hospital code stroke patients, and propose future directions for in-hospital code stroke paradigms for improved patient outcomes and quality of care.
Interferon-Gamma Release Assay Conversion and Reversion Reactions During Solid Organ Transplant Evaluation
Chiu, Chia‐Yu , Brumble, Lisa , Vikram, Holenarasipur R. , Theel, Elitza S. , Beam, Elena , Mahmood, Maryam , Vikram, Holenarasipur R. , Theel, Elitza S , Beam, Elena , Chiu, Chia-Yu , Mahmood, Maryam

Clinical Infectious Diseases | October 29, 2024 | Volume: 80 | Issue: 6 | Pages: e90-e92

10.1093/cid/ciae525 | PMID 39478320 Get It